ASCO-Ontario Health living guideline (161 RCTs) for multiple myeloma: quadruplet daratumumab or isatuximab plus bortezomib, lenalidomide and dexamethasone first line for suitable patients, lenalidomide-based maintenance, and triplet or T-cell redirecting therapy at relapse.
Guidelinen = 161 trials
Hicks et al. Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline